Overview

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
In this trial, anti-tumor efficacy of TAGRISSO in NSCLC patients in whom T790 mutations are detected by liquid biopsy.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
AstraZeneca
Treatments:
Osimertinib